BioCentury | Oct 22, 2019
Emerging Company Profile

Intrepida: Tackling the innate immune system to treat cancer

...Investments and Canaan Partners co-led the financing round with participation from Indaco Venture Partners and Vertis...
...Number of employees: 2 Funds raised: $9.5 million Investors: Sofinnova Investments, Canaan, Indaco Venture Partners, Vertis...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin/sitagliptin regulatory update

...the 3 NDAs are in December. The applications are based on data from the companies’ VERTIS...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin/metformin regulatory update

...the 3 NDAs are in December. The applications are based on data from the companies’ VERTIS...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin regulatory update

...the 3 NDAs are in December. The applications are based on data from the companies’ VERTIS...
BioCentury | Sep 26, 2016
Clinical News

Ertugliflozin: Phase III data

...Top-line data from the double-blind, international Phase III VERTIS SITA2 trial in 463 Type II diabetics...
...were presented at the European Association for the Study of Diabetes meeting in Munich. The VERTIS...
BioCentury | Jun 20, 2016
Clinical News

Ertugliflozin: Phase III data

...The double-blind, placebo-controlled Phase III VERTIS Factorial trial in 1,233 Type II diabetics inadequately controlled on...
...for both). Data were presented at the American Diabetes Association meeting in New Orleans. The VERTIS...
BioCentury | Jun 20, 2016
Clinical News

Ertugliflozin: Phase III data

...The double-blind, international Phase III VERTIS Mono trial in 461 Type II diabetics inadequately controlled on...
...for both). Data were presented at the American Diabetes Association meeting in New Orleans. The VERTIS...
BioCentury | Jun 14, 2016
Clinical News

Ertugliflozin meets in Phase III diabetes studies

...YE16, and have expanded an ongoing cardiovascular outcomes study of the candidate. In the 461-patient VERTIS...
...sitagliptin significantly reduced HbA1c at week 26 compared to either therapy alone, meeting the 1,233-patient VERTIS...
...8,000 patients in the Phase III VERTIS CV study of ertugliflozin, up from about 3,900. VERTIS...
Items per page:
1 - 8 of 8
BioCentury | Oct 22, 2019
Emerging Company Profile

Intrepida: Tackling the innate immune system to treat cancer

...Investments and Canaan Partners co-led the financing round with participation from Indaco Venture Partners and Vertis...
...Number of employees: 2 Funds raised: $9.5 million Investors: Sofinnova Investments, Canaan, Indaco Venture Partners, Vertis...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin/sitagliptin regulatory update

...the 3 NDAs are in December. The applications are based on data from the companies’ VERTIS...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin/metformin regulatory update

...the 3 NDAs are in December. The applications are based on data from the companies’ VERTIS...
BioCentury | Mar 9, 2017
Clinical News

Ertugliflozin regulatory update

...the 3 NDAs are in December. The applications are based on data from the companies’ VERTIS...
BioCentury | Sep 26, 2016
Clinical News

Ertugliflozin: Phase III data

...Top-line data from the double-blind, international Phase III VERTIS SITA2 trial in 463 Type II diabetics...
...were presented at the European Association for the Study of Diabetes meeting in Munich. The VERTIS...
BioCentury | Jun 20, 2016
Clinical News

Ertugliflozin: Phase III data

...The double-blind, placebo-controlled Phase III VERTIS Factorial trial in 1,233 Type II diabetics inadequately controlled on...
...for both). Data were presented at the American Diabetes Association meeting in New Orleans. The VERTIS...
BioCentury | Jun 20, 2016
Clinical News

Ertugliflozin: Phase III data

...The double-blind, international Phase III VERTIS Mono trial in 461 Type II diabetics inadequately controlled on...
...for both). Data were presented at the American Diabetes Association meeting in New Orleans. The VERTIS...
BioCentury | Jun 14, 2016
Clinical News

Ertugliflozin meets in Phase III diabetes studies

...YE16, and have expanded an ongoing cardiovascular outcomes study of the candidate. In the 461-patient VERTIS...
...sitagliptin significantly reduced HbA1c at week 26 compared to either therapy alone, meeting the 1,233-patient VERTIS...
...8,000 patients in the Phase III VERTIS CV study of ertugliflozin, up from about 3,900. VERTIS...
Items per page:
1 - 8 of 8